Shah Pritesh
Known title: Chief Commercial OfficerCIK: 0001744884
Associated companies
Transaction History
| NVCR | ▼ Sell | Open Market | 382 | $5K | 11/7/2023 | View on chart |
| NVCR | ▼ Sell | Open Market | 273 | $6K | 9/1/2023 | View on chart |
| NVCR | ▲ Buy | Grant | 367 | $13K | 6/30/2023 | View on chart |
| NVCR | ▼ Sell | Open Market | 1,570 | $120K | 3/3/2023 | View on chart |
| NVCR | ▼ Sell | Open Market | 16,909 | $1.3M | 3/3/2023 | View on chart |
| NVCR | ▲ Buy | Grant | 43,246 | $0 | 3/3/2023 | View on chart |
| NVCR | ▲ Buy | Grant | 3,936 | $0 | 3/3/2023 | View on chart |
| NVCR | ▼ Sell | Open Market | 2,942 | $224K | 3/3/2023 | View on chart |
| NVCR | ▼ Sell | Open Market | 937 | $71K | 3/2/2023 | View on chart |
| NVCR | ▼ Sell | Open Market | 1,923 | $147K | 3/1/2023 | View on chart |
| NVCR | ▲ Buy | Grant | 19,055 | $0 | 2/28/2023 | View on chart |
| NVCR | ▼ Sell | Open Market | 387 | $42K | 1/5/2023 | View on chart |
| NVCR | ▼ Sell | Open Market | 269 | $21K | 9/2/2022 | View on chart |
| NVCR | ▲ Buy | Grant | 312 | $18K | 7/5/2022 | View on chart |
| NVCR | ▼ Sell | Open Market | 3,669 | $261K | 3/9/2022 | View on chart |
| NVCR | ▼ Sell | Open Market | 2,481 | $174K | 3/8/2022 | View on chart |
| NVCR | ▼ Sell | Open Market | 5,294 | $368K | 3/7/2022 | View on chart |
| NVCR | ▼ Sell | Open Market | 1,914 | $135K | 3/4/2022 | View on chart |
| NVCR | ▼ Sell | Open Market | 2,632 | $193K | 3/4/2022 | View on chart |
| NVCR | ▼ Sell | Open Market | 997 | $74K | 3/3/2022 | View on chart |
| NVCR | ▲ Buy | Grant | 21,714 | $0 | 3/3/2022 | View on chart |
| NVCR | ▼ Sell | Open Market | 321 | $44K | 9/3/2021 | View on chart |
| NVCR | ▼ Sell | Open Market | 150 | $21K | 9/3/2021 | View on chart |
| NVCR | ▼ Sell | Open Market | 30 | $4K | 9/3/2021 | View on chart |
| NVCR | ▼ Sell | Open Market | 156 | $22K | 9/2/2021 | View on chart |
| NVCR | ▲ Buy | Option Exercise | 3,717 | $572K | 7/31/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
NovoCure Gains Japan Approval for Optune Pax in Pancreatic Cancer
NovoCure received regulatory approval in Japan for Optune Pax to treat pancreatic cancer. This development is significant because it expands the potential market for the company's device. Analyst notes suggest this approval may shift the investment thesis by highlighting the firm's cash generation capabilities.
NovoCure Gains Japan Approval for Optune Pax in Pancreatic Cancer. NovoCure received regulatory approval in Japan for Optune Pax to treat pancreatic cancer. This development is significant because it expands the potential market for the company's device. Analyst notes suggest this approval may shift the investment thesis by highlighting the firm's cash generation capabilities.